Dendritic Cells (DCs)-Based Cancer Immunotherapy: A Review on the Prospects of Medicinal Plants and Their Phytochemicals as Potential Pharmacological Modulators

: Dendritic cells (DCs) are specialized antigen-presenting cells in humans and animals that provide antigen-speciﬁc T-cell immunity in the body. It also establishes a linkage between innate and adaptive immune responses. Various studies have shown that malignancies or cancer may impair DCs and effector T-cell functions. DCs have now become a new molecular target for the treatment of cancer. Modiﬁed matured DCs could be novel biological modiﬁers to treat various diseases, including cancer. This review aims to provide an update on the impacts of various plant materials and their phytochemicals on DC-based cancer immunotherapy. Existing literature on DC-based cancer immunotherapy and plant-based pharmacological modulators has been explored over the last decade using various online databases such as Google Scholar, PubMed, Science Direct, and Scopus. Mounting evidence from preclinical and clinical ﬁndings suggests that various plants and their bioactive phytochemicals are effective in modulating the immune system and signaling pathways involved in anti-tumor immunity. Despite the prospective role of herbs in DC-based cancer immunotherapy, most of the studies are limited by either preclinical models or crude plant extracts. This review provides a useful perspective for developing potential plant-derived pharmacological modulators in DC-based cancer immunotherapy.


Introduction
Dendritic cells (DCs) are dominant antigen-presenting cells and play a vital role in processing and presenting antigens to T-cells that can be directed to humoral and cellular antigen-specific immune responses against specific benign and malignant tumors [1]. Mouse and human DCs seem to be similar or parallel. It has been reported that DC precursors existing in the bone marrow are categorized into two groups on the basis of their localization: lymphoid organ resident DCs and migratory tissue DCs [2,3]. The DCs, which reside in lymphoid organs, uptake antigens from blood and transfer them to the local T cells. In contrast, DCs in migratory tissues transfer antigens from tissues to the lymph node and present antigens from tissues to T-cells. On the basis of the marker on the cell surface, the DCs are divided into two groups in mice: one is conventional DCs and the other is plasmacytoid DCs (pDCs). The pDCs release a huge amount of type 1 interferon due to viral infections [4].
Immature DCs have the capacity to uptake and process antigens, which are subsequently converted to matured DCs and migrate to the target lymphoid organs [5]. Matured DCs are characterized by a high level of major histocompatibility complex (MHC) as well as related co-stimulatory molecules such as CD80, CD83, and CD86 that stabilize the interaction between DCs and naive T lymphocytes [6]. The mature DCs produce proinflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin 12 (IL-12), which activate Th1 cells and catalyze the activation of cytotoxic T lymphocytes. Activated cytotoxic T lymphocytes (CTL) migrate to the tumor microenvironment and induce apoptosis via the release of perforin and granzymes. Dendritic cells can also induce natural killer (NK) cells and B cells [7]. Pro-inflammatory cytokines such as IL-12, IL-6, and tumor necrosis factor-α (TNF-α), produced mainly by DCs, alter the tumor microenvironment as well as induce the cytotoxic activity of NK cells and clonal expansion of CD4 + and CD8 + T-cells [8]. Some proinflammatory cytokines (TNF-α, IL-1 α/β and IL-6) can induce an immune response in the tumor microenvironment. They also produce reactive oxygen species (ROS) and reactive nitrogen species (RNS) that infiltrate the tumor microenvironment and destroy tumor cells [9,10]. The malignant can inhibit or inactivate DCs or effector T-cells by secreting inhibitory molecules or immunosuppressive cytokines (IL-10 and TGF-β) [11]. The dendritic cells present extracellular antigens on MHC-II molecules to CD4+ T cells and, on the other hand, intracellular antigens on MHC-I molecules to CD8+ T cells.
The dendritic cells not only present extracellular antigens on MHC-II molecules to CD4 + T-cells but also present intracellular antigens on MHC-I molecules to CD8 + T-cells, which play a pivotal role in anticancer immunity [12]. The dendritic cells present antigens to helper T cells and produce distinct Th1, Th2, Th17, and follicular T cells. Based on cytokine expression, Th1 and Th2 cells produce IFN-γ and IL-4, IL-5, and IL-13, respectively. Th17 cells show a great degree of change and convert to Th1 cells. Anticancer immunity is provided by IFN-γ-producing T helper cells [13]. Over the last decade, ex vivo generated DCs and in vitro targeting DCs have been extensively studied as potential cancer vaccines [11]. Meanwhile, several DC-based cancer vaccine trials against specific antigens have been conducted, such as ovarian cancer, prostate cancer, metastatic melanoma cancer, glioblastoma, and pancreatic cancer [14]. However, it has been reported that DC-based cancer vaccines are not so effective in clinical trials due to low maturation, migration, and reduced IL-12 secretion [15,16]. For this reason, the ex vivo-generated DCs need to be stimulated by adjuvant to make fully matured DCs with increased IL-12 secretion from these cells [17]. Recently, the Food and Drug Administration of the USA approved a DCbased vaccine against human prostate cancer named Sipuleucel-T. It has been shown that early-stage of clinical trials of DC-based cancer vaccines increase the nonspecific immune responses in cancer patients with aggressive tumor progression and immune dysfunction that limit the effectiveness of the vaccines [11,18]. To overcome this problem, tumor cell lysate (TCL)-loaded DCs with phytomolecule adjuvant increased the effectiveness of vaccines in an in vivo animal model [18].
The medicine from plant extracts and its active components has immunomodulatory effects on the maturation of DCs [19,20]. Plant-derived polysaccharides (PDPs) can stimulate the maturation of DCs and present internalized antigens to naive T-cells. The naive T-cells activate T-cells and remove the tumor. The plant-derived polysaccharides (PDPs) can also be used as adjuvants in DC-based cancer vaccines or act as independent agents in intrinsic anti-tumor activities [21]. Mixed polysaccharide fractions from plant roots enhance the efficiency of the DC-based cancer vaccine against metastasis of 4T1 mammary carcinoma in mice [18]. Traditional herbal medicine can reduce the toxicity of chemotherapy and radiotherapy and enhance anti-tumor therapies with decreased cancer-derived pains#. It also reduces postoperative complications and increases the survivability of cancer patients [22]. Another report showed that immunomodulatory activity on the human Monocyte-Derived Dendritic Cell (MDDCs) vaccine, which was pulsed with plant extract and human papillomavirus 16 (HPV16) tumor protein and was shown to be effective against HPV16 related tumors in an animal model [23]. Plant extract of Oregon grape (Mahonia aquifolium) stimulates peripheral blood mononuclear cells (PBMCs) and induces cytotoxicity and apoptosis of the tumor cells [24]. Kauroo et al. investigated Mauritius endemic plants (Psiadia lithospermifolia, plants from the Asteraceae family) for anticancer activities in T-cell lymphoma and melanoma cells. They also found that plant extract components have potential anticancer activities in vitro studies [25]. Plant tuber extract (Dioscorea alata var. purpurea) acts as an adjuvant of bone-marrow-derived dendritic cell (DC) based vaccine for cancer immunotherapy [26]. The maturation of dendritic cells is important for initiating immune responses. The tumor microenvironment inhibits the maturation of DCs, and it is a great problem for DC-based tumor immunotherapy. PDPs induce phenotypic and functional maturation of DCs [27]. Alcoholic extracts of plants (Tinospora cordifolia) induce the differentiation of dendritic cells from macrophages in the presence of granulocyte-macrophage colony-stimulating factor (GMCSF), TNF, and IL-4 [28]. It has been proven that most therapeutic plants can modulate DC activities and can be used as a therapeutic target to treat cancer [29]. For this reason, this review discusses the potential application of phytochemicals in dendritic cell (DC)-based cancer immunotherapy.

Dendritic Cells Differentiation and Maturation
Although the immature DCs have high endocytic activity to capture antigens and the ability to initiate T-cell stimulation [30]. The maturation of DCs is necessary for antigenspecific T-cell immunity [31]. Different types of proinflammatory cytokines (IL-1, TNFα, PGE2, etc.), lipopolysaccharide (LPS) from bacteria and natural products induce DC maturation. Mature DCs show surface expression of costimulatory molecules such as CD40, CD80, CD86, and MHC II, which are essential to produce an antigen-specific T cell immune response [4,29]. It has been reported that different types of plant extracts and their active components have been shown to enhance DC differentiation (Table 1). Pine cone extract, the traditional Japanese herbal plant kampo, and water-soluble extract of the fern Polypodium leucotomos induce DC differentiation both in vitro and in vivo [29].
Plant-derived polysaccharide (PDP) extracts induce DC maturation and provide antitumor immunity [21]. Plant polysaccharides obtained from the medicinal herb Polyporus umbellatus induce activation and maturation of murine BMDC through TLR [32]. Another study also showed that plant polysaccharide (PLP) from Pueraria lobata induces surface phenotype expression of CD40, CD86, and major histocompatibility complex I/II [27]. The Dioscorea plant extract (DsII polysaccharides) increased the maturation of DCs and also enhanced the TCL-loaded DC-mediated T-cell activation and proliferation, which induces strong immunity against melanoma in animals [26]. It has been found that a plant of Nicotiana benthamiana does not affect dendritic cell differentiation but induces maturation. The plant does not have any effect on antigen uptake capacity [23]. Neem leaf glycoprotein (NLGP) induces the maturation of DCs and also increases the expression of MHCs and co-stimulatory molecules CD83, CD80, CD86, and CD40 [33]. Dendritic cells pulsed with Astragalus polysaccharide showed increased DC maturation and induced allogeneic lymphocyte proliferation. It also increased the expression of CD11c and MHC class II molecules on DCs [34,35]. The immunomodulatory effect of aged garlic extract 14 kDa protein showed increased expression of CD40 surface phenotypes of DCs, but it had no effect on CD86 and MHC II expressions [36]. The seed extract of Plantago asiatica induces the maturation of DCs and also increases the expression of MHC II, CD80, and CD86 surface phenotypes on DCs [37]. Medicinal herbs, including Thymus daenensis, Thymus vulgaris, and Zataria multifora, combinedly induce DC-mediated T-cell activation. The herbs also showed increased CD40 surface phenotype expression on DCs [38]. Bordbar et al. showed that licorice roots containing 18-α and 18-β-glycyrrhetinic acid stimulate DCs that enhance Tcell immunity against specific antigens [39]. Some plant components were found to initiate DC differentiation and maturation in vitro, such as lupine acetate of cortex periplocae, the aqueous and organic fractions from Petiveria alliacea, an acidic polysaccharide from ginseng (Panax ginseng), and Lycium bararum polysaccharide (LBP) [29]. In the same way, another traditional Chinese herb, Achyranthes bidentata, induces surface phenotypes and maturation of DCs and also boosts immune responses in mice [40]. The fermented mistletoe extract component matures DC S and is used as an adjuvant for the treatment of cancer patients [41]. Table 1. Plant extracts on dendritic cells (DCs) differentiation and maturation.

Activation of T-Cells
It has been found that several plant components stimulate mature DCs to induce T-cell proliferation [42], which are given in Table 2. The plant-derived polysaccharide Angelica gigas Nakai (Angelin) activates DCs increases T-cell proliferation. It also increases Th1 cytokines such as IL-12 and IFN-γ [43,44]. Capparis spinosa polysaccharides induce DC maturation and increase the proliferation of CD8 and CD4 T-cells [45]. Another study showed that Safflower Carthamus tinctorius enhances DC-mediated T-cell polarization and increases the cytotoxic activity against tumors [46]. Water extract of Glycyrrhizia uralensis stimulated DC maturation, enhanced HPV16 specific CD8+ T-cell proliferation and reduced tumor size [47]. Dioscorea tuber phytoextracts confer immunomodulatory activities through DC-mediated activation of T-cell proliferation [18]. Immunomodulatory activity of plant extract (Nicotiana benthamiana) containing HPV16-E7 protein in human monocyte-derived dendritic cells induces HPV16-E7 specific cytotoxic activity [23]. Another report showed that plant-derived polysaccharides (PDPs) can induce DC maturation and provide T cell immunity [21]. The butanol fraction of the stems and leaves of Echinacea purpurea significantly influences BMDC maturation and T-cell proliferation [29]. It has been observed that uncarinic acid C, uncarinic acid D, and triterpene esters isolated from Uncaria rhynchophyla plants were found to activate cytokine production of human DCs towards Th1 immune responses [48]. Table 2. Plant extract pulsed DCs on T-cell activation.

Cytokines Production
Many studies observed that plant extracts stimulated matured DCs to increase Tcell proliferation and production of immunostimulatory cytokines such as the T helper cytokines (Th1) IL-12 and IFN-γ [49], which are shown in Table 3. The extract of the Kurosengoku Japanese soybean initiates the production of IFN-γ and IL-12 from DCs [50]. Another group found that the active component galactomannan isolated from the Caesalpinia spinosa plant gives rise to the maturation of DCs and also increases mRNA levels of proinflammatory cytokines [51]. Water extract of Glycyrrhiza uralensis stimulates the maturation of DCs and expands the concentration of proinflammatory cytokines IL-12, TNF-α. IL-6, IL-6, and IL-1β, and these changes initiate the Th1 immune response and provide cytotoxicity against tumors [47]. Plant-derived polysaccharides from Ficus carica facilitate the maturation of DCs and increase the mRNA expression of IFN-γ, IL-1, IL-6, and IL-23 [52]. Angelan from the medicinal plant Angelica gigas Nakai initiates dendritic cell maturation and increases the production of inflammatory cytokines IL-1β, TNF-α, IL-12, IFN-α, and IFN-β [43]. The polysaccharides from Astragalus mongholicus stimulated DCs to induce the expression of IL-12p70 [35]. Polysaccharide (PLP) isolated from Pueraria lobata and Mori fructus acts on DCs and increases the production of interleukin IL-1β, TNF-α, and IL-12 [27,53]. Seeds of Plantago asiatica induce DC maturation and production of increased TNF-α and IL-12p70, and decreased IL-10 [54]. Water extract of Pleurotus ferulae enhances the maturation of DCs through the Toll-like receptor4 (TLR4) signaling pathway and increases the production of IL-6, IL-12, and TNF-α in a dose-dependent manner [55]. A purified polysaccharide isolated from Polyporus 7u prompts the activation of bone marrowderived DCs and the production of IL-12 cytokines [32]. Plant-derived polysaccharides from Angelica gigas and Capparis spinosa stimulated DCs to enhance the production of IL-1β, TNF-α, IL-12, IFN-α, and IFN-β cytokines [44,45]. Ethanol extract of Phyllantus amarusgenerated tumor lysate pulsed monocyte-derived DCs induces the mRNA expression of IL-6 and IL-12 cytokines [14]. The polysaccharides from Ficus carica promote DC maturation and increase mRNA expression of IL-6, IL-12, IL-23, and IFN-γ [52]. Table 3. Plant extracts stimulated DCs on immunostimulatory cytokines production.

Plant Extracts Pulsed DCs-Based Anti-Tumor Immunity through Various Signaling Pathways
The maturation of DCs is critical for initiating immune responses. In Table 4, plant extract polysaccharide (PLP) from Pueraria lobata-activated DCs enhances T-cell stimulation through the TLR4 signaling pathway. Here, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK) phosphorylation, and nuclear factor kappa-light-chain-enhancer of activated B cells p65 (NF-κBp65) subunit are the downstream molecules of Toll-like receptor 4 (TLR4) [27]. It has been reported that neem leaf glycoprotein (NLGP) is popular for its anti-tumor therapy. NLGPpulsed DCs activate forkhead box P3+ (FoxP3+) Treg downregulation, T-bet upregulation, signal transducer and activator of transcription (STAT) 1 and STAT4 high phosphorylation, and STAT3 low phosphorylation, which ultimately induces Th1 immune response [4]. Huang et al. reported that polysaccharide from Plantago Asiatica induces DC maturation through the TLR4 pathway [54]. Water extract of Glycyrrhiza uralensis dose-dependently promotes DC maturation and cytokine production through the Toll-like receptor (TLR) 4 signaling pathway [47]. The polysaccharide-derived from Mori fructus and Platycondon grandiflorum-pulsed DCs mediated T-cell proliferation through mitogen-activated protein kinase MAPK (increased phosphorylation of JNK, ERK, c-Jun, p38 and MAPKs) and NF-κB (increase nuclear translocation of NF-κB p65 and iKBα/β degradation) signaling pathway where TLR4 is a membrane target molecule [53,56]. Angelan from Angelica gigas Nakai plant polysaccharide stimulated dendritic cells mediated tumor immunotherapy, where TLR4 is a membrane target and downstream signaling molecules are NF-κB/Rel (increased translocation of NF-κB p50/p65, RelB and c-Rel) and MAPK (increased phosphorylation of p38, JNK, and ERK) [43,44]. Another study found that Lycium barbarum polysaccharides induce TLR2 and TLR4-mediated functional activation of DCs via activation of NF-κB [57]. Li et al. reported that maturation of dendritic cells is induced by Radix Glycyrrhizae polysaccharide through NF-κB and MAPK (increased MAPK, p38, and JNK phosphorylation but no change in ERK) signaling pathways [58]. Fractioned Dioscorea phytoextrct (DsII) enhances the potency of DC-based cancer immunotherapy through pathogen-associated molecular pattern (PAMP) signaling, which is required for potent activation of naive T-cells [18]. Table 4. Plant extracts pulsed DCs on various signaling pathways in anti-tumor immunity.

Plant Extracts Pulsed DCs on In Vivo Cancer Immunotherapy
Various studies have been conducted on animal models to evaluate the effects of different plant extract components on DC-based cancer immunotherapy in vivo (Table 5). Polysaccharides from Astragalus membranaceus and Astragalus mongholicus injected in laboratory mice inhibit the growth of metastatic lung cancer [59]. Treatment of H22-bearing mice (Hepatoma) with plant extracts polysaccharide LBP (Lycium barbarum) stimulated DCs enhances the anti-tumor function [60]. Another study found that an extract of Larix leptolepsis, one of the renowned woods in Hokkaido, Japan, promotes type 1 immune response and inhibits tumor growth in mice [61]. Furthermore, grape seed proanthocyanidins decrease UV-induced immune function by repairing DNA on functional activation of DCs in mice [62]. Tinospora cordifolia is an alcoholic extract that boosts the dendritic cell differentiation of tumor-associated macrophages, enhancing tumor cytotoxicity and increasing the survivability of tumor-bearing mice [28]. The immunostimulatory plant DNA CpG activates DCs and inhibits the growth of tumors in mice by stimulating the secretion of surface phenotypes of co-stimulatory molecules, MHC and IL-12 cytokines from BMDCs [63]. In mice, CM-Glucan (carboxymethylated Beta-(1,3) (1,6) glucan); brand name Immunomax ® injection) significantly inhibits tumor growth and increases the survivability of mice through activation of DCs via TLR4 and natural killer cells [64]. The fractions of polysaccharide derived from the root of Ficus carica enhance the efficacy of DCbased cancer immunotherapy [52]. Plant-derived polysaccharide from Carthamus tinctorius provides the anti-tumor activity of DC-derived vaccines via polarization of Th1 cytokines and promotes cytotoxic activity [46]. Reishi mushroom Ganoderma lucidum-derived plant polysaccharide has immunomodulatory, antiangiogenic, and cytotoxic activity against tumors in mice [65]. The polysaccharide from Dioscorea alata var. Purpurea stimulates DCs and enhances anti-tumor activity in mice [26].

Plant Name/Extracts DCs on In Vivo Study against Cancer References
Polysaccharide LBP (Lycium barbarum) Increase the number of DCs with anti-tumor immune function in mice [60] Larix leptolepsis Activates DCs to initiate type 1 immunity and inhibit tumor growth in mice [61] Grape seed proanthocyanidins Lowering the UV-induced immunosuppression by repairing DNA through activation of DCs in mice [62] Alcoholic extract of Tinospora cordifolia Enhancing the differentiation of tumor-associated macrophages to DCs and increases cytotoxicity in tumor bearing mice [28] Plant DNA CpG Activates DCs and decreases tumor growth in mice [63] Plant-derived agonist CM-Glucan (carboxymethylated Beta-(1,3) (1,6) glucan); trade name Immunomax ® Inhibit tumor growth in mice through activation of DCs [64] Polysaccharide from root of Ficus carica Enhancing the activity of DC-based cancer immunotherapy in mice [52] Polysaccharide from Carthamus tinctorius Increase the efficiency of DC-based cancer vaccine through the cytotoxic activity of CD8 T-cells [46] Polysaccharide from Dioscorea alata var. Purpurea Stimulates DCs and enhances anti-tumor activity in mice [26]

Application of Phytoextract in DCs-Based Clinical Study of Cancer Therapy
Dendritic cells play an important role in the initiation of immune responses for anticancer immunity. In cancer patients, dendritic cells are altered in the tumor microenvironment [1]. For this reason, modulation of DCs is suggested for cancer prevention and treatment. In the last couple of years, several studies have been performed to assess the role of plant extract in DC-based immunotherapy against cancer [66]. In Table 6, it has been reported that Nicotiana benthamiana NbPVX-E7 pulsed-MDDCs/PBMCs can prime human blood-derived lymphocytes from healthy individuals to induce human papillomavirus (HPV16 E7) specific cytotoxic activity [23]. Dendritic cell activation was observed in breast cancer patients who were given the Chinese herbal medicine Shenqi Fuzheng [67]. Another study showed that Lingdankang composite and DC cytokine-induced killer cells were effective against leukemia patients [68]. NLGP overcomes the indoleamine 2,3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T-cells in cervical cancer (stage IIIB) patients [69]. Furthermore, DCs exposed to Amomi Semen extract exhibited activated phenotypes of DCs and also secreted IL-12p70 cytokines, which inhibited the growth of tumor cells [70]. A traditional herb named Juzen-taiho-to is used in East Asia for the treatment of cancer patients. The glycolipid mixture containing Bglucosylceramides stimulates primary DCs that express intercellular adhesion molecule-1 (ICAM 1), triggering an immune response [50]. Lipid-soluble extract of Pinellia pedatisecta Schott stimulates intratumoral dendritic cell activation through suppressor of cytokine signaling 1 (SOCS1) in cervical cancer patients [71]. NLGP-pulsed DCs overcome the hyperactivity of regulatory cells in stage III cervical cancer patients [69]. Table 6. Plant extracts on DCs-based clinical study against cancer.

Plant Name/Extracts DCs-Based Clinical Study against Cancer References
Nicotiana benthamiana NbPVX-E7 pulsed-MDDCs/PBMC Increase cytotoxic activity against HPV16 E7 [23] Chinese herbal medicine Shenqi Fuzheng DCs activation in breast cancer patients [67] Lingdankang composite combined DCs and cytokines Effective against leukemia patients [68] Neef leaf glycoprotein (NLGP) Dendritic cells attenuating hyperactive regulatory T-cells in cervical cancer (stage IIIB) patients [69] DCs exposed to Amomi Semen extract Activation of phenotypes of DCs and inhibits the growth of tumor cells [70] Glycolipid mixture containing B-glucosylceramides from herb DCs expressed ICAM 1 in cancer patients [50] Lipid-soluble extract of Pinellia pedatisecta Schott Stimulates intratumoral dendritc cell activation in cervical cancer patients [71]

Methodology and Search Strategy
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [72,73]. Online databases such as PubMed, Google Scholar and Scopus were accessed to retrieve published literature using the MeSH terms "dendritic cells" AND "cancer immunotherapy" AND "plants" AND "phytochemicals" AND "immunopharmacology". Literature published in the last two decades was retrieved. For screening purposes, automatic search tools were used to remove some of the articles, on the other hand, others were screened manually. The articles which were published in languages other than English were removed during screening time. Reviews, book chapters, and conference papers were also excluded from this review. A total of 61 studies, including 45 in vitro studies, nine preclinical in vivo studies, and seven clinical trials, were retrieved and discussed in this study (Figure 1). The information obtained from research articles was systemized in the table.
Appl. Sci. 2022, 12, x FOR PEER REVIEW 9 of 14 Lingdankang composite combined DCs and cytokines Effective against leukemia patients [68] Neef leaf glycoprotein (NLGP) Dendritic cells attenuating hyperactive regulatory T-cells in cervical cancer (stage IIIB) patients [69] DCs exposed to Amomi Semen extract Activation of phenotypes of DCs and inhibits the growth of tumor cells [70] Glycolipid mixture containing Bglucosylceramides from herb DCs expressed ICAM 1 in cancer patients [50] Lipid-soluble extract of Pinellia pedatisecta Schott Stimulates intratumoral dendritc cell activation in cervical cancer patients [71]

Methodology and Search Strategy
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [72,73]. Online databases such as PubMed, Google Scholar and Scopus were accessed to retrieve published literature using the MeSH terms "dendritic cells" AND "cancer immunotherapy" AND "plants" AND "phytochemicals" AND "immunopharmacology". Literature published in the last two decades was retrieved. For screening purposes, automatic search tools were used to remove some of the articles, on the other hand, others were screened manually. The articles which were published in languages other than English were removed during screening time. Reviews, book chapters, and conference papers were also excluded from this review. A total of 61 studies, including 45 in vitro studies, nine preclinical in vivo studies, and seven clinical trials, were retrieved and discussed in this study (Figure 1). The information obtained from research articles was systemized in the table.

Conclusions and Future Aspects
Dendritic cells are a potential target for the development of anti-cancer immunotherapy. In recent years, various approaches for the maturation of DCs and the initiation of anticancer immune responses have been introduced. Nonetheless, DC-based immunotherapy did not lead to satisfactory outcomes in clinical cases. Occasionally, DCs generated in in vitro studies have been found to be defective and unable to migrate to lymph nodes. In some cases, low cellular infiltration increased the number of immunosuppressive cells and low cytotoxic activities were seen in DC-based tumor immunotherapy. For immunotherapy, several molecules with maturing DCs have been used for cancer treatment. Plants and plant-derived purified pulsed dendritic cell products show promise in cancer treatment ( Figure 2). It is expected that DC-based immunotherapy will produce some promising results in the next 5 to 10 years. Although plant extracts have many beneficial properties, there are many limiting effects on the mechanism of action and molecular targets that prevent their development as therapeutics. More extensive studies need to be investigated for the benefits of herbal or herbal products in DC-based cancer treatment with low cost and minimal side effects.

Conclusions and Future Aspects
Dendritic cells are a potential target for the development of anti-cancer immunotherapy. In recent years, various approaches for the maturation of DCs and the initiation of anticancer immune responses have been introduced. Nonetheless, DC-based immunotherapy did not lead to satisfactory outcomes in clinical cases. Occasionally, DCs generated in in vitro studies have been found to be defective and unable to migrate to lymph nodes. In some cases, low cellular infiltration increased the number of immunosuppressive cells and low cytotoxic activities were seen in DC-based tumor immunotherapy. For immunotherapy, several molecules with maturing DCs have been used for cancer treatment. Plants and plant-derived purified pulsed dendritic cell products show promise in cancer treatment (Figure 2). It is expected that DC-based immunotherapy will produce some promising results in the next 5 to 10 years. Although plant extracts have many beneficial properties, there are many limiting effects on the mechanism of action and molecular targets that prevent their development as therapeutics. More extensive studies need to be investigated for the benefits of herbal or herbal products in DC-based cancer treatment with low cost and minimal side effects.

Conflicts of Interest:
The authors declare no conflict of interest.